Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Marginal Zone Lymphoma

B-cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Bendamustine Hydrochloride

Rituximab

Antineoplastic Agents, Immunological

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2

Rituximab and Bendamustine

Carlos Montalbán, MD

Antonio Salar, MD

Ana Muntañola, MD

Mª José Rodríguez, MD

María José Terol, MD

Juan Manuel Sancho, MD

Eva Domingo, MD

Grande Carlos, MD

Carlos Panizo, MD

Miguel Canales, MD

Raquel Oña, MD

Reyes Arranz, MD

Dolores Caballero, MD

José Luis Bello, MD

Joan Bargay, MD

Luis Palomera, MD

Franciaco Javier Peñalver, MD

Eulogio Conde, MD

José Javier Sánchez-Blanco, MD

Concepción Nicolás, MD

The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.

Primary endpoint:

* Event-free-survival (EFS) (failure or death from any cause) for all patients.

Secondary endpoints:

* Complete and partial remission rates for all patients
* Response duration (time to relapse or progression) for responder patients
* Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients
* Overall survival for all patients
* Acute and long-term toxicity

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Lymphoma, Follicular

Follicular Lymphoma

Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.

Evaluate the effectiveness of rituximab, bendamustine (r) in terms of complete response and response complete not confirmed.

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

Evaluation of response to induction treatment at 6 months after inclusion of the patient. Evaluation of response to maintenance treatment at 2 years after finishing the induction treatment.

Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma	NCT01015248	MALT LYMPHOMA	Rituximab and B...	18 Years - 84 Years	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line	NCT01127841	Follicular Non-...	Rituximab and B...	18 Years -	Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma	NCT01015248	MALT LYMPHOMA	Rituximab and B...	18 Years - 84 Years	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Spots Global Cancer Trial Database for rituximab and bendamustine